Myovant Sciences (Myovant Sciences) Earnings per Share (Diluted) : $-1.91 (TTM As of Dec. 2022)

View and export this data going back to 2016. Start your Free Trial

What is Myovant Sciences Earnings per Share (Diluted)?

Myovant Sciences's Earnings per Share (Diluted) for the three months ended in Dec. 2022 was $-0.59. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2022 was $-1.91.

Myovant Sciences's EPS (Basic) for the three months ended in Dec. 2022 was $-0.59. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2022 was $-1.91.

Myovant Sciences's EPS without NRI for the three months ended in Dec. 2022 was $-0.59. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2022 was $-1.91.

During the past 3 years, the average EPS without NRIGrowth Rate was 18.40% per year. During the past 5 years, the average EPS without NRI Growth Rate was -4.80% per year.

During the past 7 years, Myovant Sciences's highest 3-Year average EPS without NRI Growth Rate was 18.40% per year. The lowest was -25.60% per year. And the median was -5.50% per year.

Myovant Sciences Earnings per Share (Diluted) Historical Data

The historical data trend for Myovant Sciences's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Myovant Sciences Earnings per Share (Diluted) Chart

Myovant Sciences Annual Data

Trend

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Earnings per Share (Diluted)

Get a 7-Day Free Trial

-2.41

-4.09

-3.37

-2.83

-2.22

Myovant Sciences Quarterly Data
	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
Earnings per Share (Diluted)	Get a 7-Day Free Trial															-0.68	-0.63	-0.22	-0.47	-0.59

Competitive Comparison of Myovant Sciences's Earnings per Share (Diluted)

For the Biotechnology subindustry, Myovant Sciences's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Myovant Sciences's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Myovant Sciences's PE Ratio distribution charts can be found below:

* The bar in red indicates where Myovant Sciences's PE Ratio falls into.

Myovant Sciences Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Myovant Sciences's Earnings Per Share (Diluted) for the fiscal year that ended in Mar. 2022 is calculated as

Diluted Earnings Per Share (A: Mar. 2022 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-205.981	-	0)	/	92.975
	=	-2.22

Myovant Sciences's Earnings Per Share (Diluted) for the quarter that ended in Dec. 2022 is calculated as

Diluted Earnings Per Share (Q: Dec. 2022 )	=	(Net Income	-	Preferred Dividends	/	Shares Outstanding (Diluted Average)
	=	(-57.627	-	0)	/	96.859
	=	-0.59

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.91

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.

Myovant Sciences (NYSE:MYOV) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Myovant Sciences Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Myovant Sciences's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

Myovant Sciences (Myovant Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Myovant Sciences Ltd (NYSE:MYOV) » Definitions » Earnings per Share (Diluted)

Comparable Companies

Traded in Other Exchanges

N/A

Address

11-12 St. James’s Square, Suite 1, 3rd Floor, London, GBR, SW1Y 4LB

Website

https://www.myovant.com

Myovant Sciences Ltd is a healthcare company focused on redefining care for women and for men. The company's lead product candidate is relugolix, a once-daily, oral GnRH receptor antagonist. It has three late-stage clinical programs for relugolix in uterine fibroids, endometriosis, and prostate cancer. The company is also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, that has completed a Phase 2a study for the treatment of female infertility as part of assisted reproduction.

Executives

Sumitomo Chemical Co., Ltd.	10 percent owner	7-1, NIHONBASHI 2-CHOME, CHUO-KU, TOKYO M0 103-6020
Lauren Merendino	officer: Chief Commercial Officer	C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
David C Marek	director, officer: Principal Executive Officer	C/O WEBMD HEALTH CORP., 111 EIGHTH AVENUE, NEW YORK NY 10011
Matthew Lang	officer: General Counsel & Corp. Secy.	C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
Ferreira Juan Camilo Arjona	officer: Chief Medical Officer	C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
Uneek Mehra	officer: Principal Financial Officer	C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
Shigeyuki Nishinaka	director	5281 CALIFORNIA AVENUE, SUITE 100, IRVINE CA 92617
Nancy Valente	director	C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
Terrie Curran	director	C/O MYOVANT SCIENCES INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018
Frank Karbe	officer: Principal Fin'l & Accounting	C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
Kim Sablich	officer: Chief Commercial Officer	C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, BRISBANE CA 94005
Hiroshi Nomura	director	C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, BRISBANE CA 94005
Sumitovant Biopharma Ltd.	10 percent owner	C/O ROIVANT SCIENCES, INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018
Dainippon Sumitomo Pharma Co Ltd	10 percent owner	6-8 DOSHOMACHI 2-CHOME, CHUO-KU, OSAKA M0 541-0045
Adele M. Gulfo	director	ONE NEENAH CENTER, 4TH FLOOR, P.O. BOX 669, NEENAH WI 54957